Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to assess the overall safety and tolerability of a single
intravenous infusion of three doses of Mesenchymal Precursor Cells versus Placebo in subjects
with Type 2 Diabetes inadequately controlled on Metformin.